Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Beijing Biotech
Actuate Therapeutics Inc.
Bristol-Myers Squibb
RasCal Therapeutics, Inc.
Filamon LTD
AstraZeneca
Hoffmann-La Roche
Essen Biotech
Var2 Pharmaceuticals
Novartis
Mayo Clinic
Mayo Clinic
Degron Therapeutics Co.
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Day One Biopharmaceuticals, Inc.
LigaChem Biosciences, Inc.
Ikena Oncology
Washington University School of Medicine
Day One Biopharmaceuticals, Inc.
Jonsson Comprehensive Cancer Center
Apollomics Inc.
Columbia University
Stanford University
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
BerGenBio ASA
Universidade Federal de Pernambuco
ABM Therapeutics Corporation
Wake Forest University Health Sciences
Mayo Clinic
Cedars-Sinai Medical Center
Sumitomo Pharma America, Inc.
Hoffmann-La Roche
Quadriga Biosciences, Inc.
Health Clinics Limited
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Gilead Sciences
Hospices Civils de Lyon
University Hospital Tuebingen
Southwest Hospital, China
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.
Chinese PLA General Hospital
Shenzhen BinDeBio Ltd.
Stanford University